ReportWire

Tag: Respiratory Diseases and Disorders

  • Race-Neutral Testing Could Have Given Access to Life-Saving Lung Transplants for More Black Patients

    Race-Neutral Testing Could Have Given Access to Life-Saving Lung Transplants for More Black Patients

    [ad_1]

    Newswise — June 21, 2023 – NEW YORK, NY— Race-neutral lung function interpretation could increase access to lung transplants for Black patients with respiratory disease, according to new research published in the Annals of the American Thoracic Society online ahead of print.

    In “Race-Specific Interpretation of Spirometry: Impact on the Lung Allocation Score,” lead researcher J. Henry Brems, MD, MBE of the Johns Hopkins School of Medicine, and colleagues investigated how race-specific versus race-neutral equations alter the lung allocation score (LAS) and the priority for lung transplant across races. The lung allocation score determines which patients get priority on the lung transplant listing.

    A group of 8,982 patients were selected from the United Network for Organ Sharing database and the LAS calculated for each patient from both a race-specific and race-neutral approach. Dr. Brems noted that “that a race-specific approach to lung function interpretation has the potential to systematically bias care to the disadvantage of Black patients with respiratory disease.”

    He added that, “our results support the recent shift in ATS recommendations to use race-neutral equations as a way to advance the equitable care of respiratory disease.”  In a press release announcing the American Thoracic Society’s official statement on race, ethnicity and pulmonary function test interpretation, the lead author of the statement noted: “Reviews of clinical algorithms throughout medicine in the past decade have spawned concerns about bias and harm when race is used as a variable and has led to revisions of these algorithms.”

    The degree of harm that may result from bias is critical to examine as lives literally hang in the balance. Lung transplantation is a life-saving option for people with end-stage lung disease. Candidates for a transplant are assigned an LAS score, which is based on – among other things – age, oxygen requirement and lung function test results. A high LAS score will give a patient a higher priority on the transplant list.

    In this latest study, the researchers found that “Compared to a race-neutral approach, a race-specific approach resulted in a lower LAS for Black patients and higher LAS for white patients, which may have contributed to racially biased allocation of lung transplants.”

    As medicine shifts to a race-neutral approach in disease evaluation and management, more studies will be needed to understand the impact on patient care. “We may need to develop alternative or more holistic approaches to replace current threshold-based decisions, which are used for some diagnostic criteria, treatments, referrals, disability benefits, and even employment eligibility for some occupations,” said Dr. Brems.

     

    Share via Twitter: Race-neutral testing could give access to life-saving #lung transplants for more Black patients. Read the latest now. [link to study] @AnnalsATS @HenryBrems @HopkinsMedicine

     

     

    [ad_2]

    American Thoracic Society (ATS)

    Source link

  • Long COVID, Chronic Fatigue Syndrome Share Biological Abnormalities

    Long COVID, Chronic Fatigue Syndrome Share Biological Abnormalities

    [ad_1]

    Newswise — Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome are debilitating conditions with similar symptoms. Neither condition has diagnostic tests or treatments approved by the Food and Drug Administration (FDA) and each cost the United States billions of dollars each year in direct medical expenses and lost productivity. Doctors and researchers have wondered what are the underlying biological abnormalities that may cause symptoms, and whether these abnormalities are similar in the two illnesses.

    A review article authored by senior investigators at Brigham and Women’s Hospital and Harvard Medical School, and the Mailman School of Public Health and Vagelos College of Physicians and Surgeons of Columbia University, addresses these questions. In it, the authors review 559 scientific publications. The authors compared the symptoms of both conditions, noting their great similarity, and then showed that very similar underlying biological abnormalities have been found in both conditions, abnormalities involving the brain, immune system, heart, lungs, gut, and energy metabolism.

    “By making a side-by-side comparison of what is known about each type of abnormality, in each of these two illnesses, our review serves as a ‘road map’ to identify areas that require further research,” said Anthony L. Komaroff, MD, senior physician in the Brigham Department of Medicine and professor of medicine at Harvard Medical School.  “We hope that identifying those abnormalities for which the evidence is strongest will help focus the search for improved diagnostic tests and effective treatments.”

    Read more in Frontiers in Medicine.

    [ad_2]

    Brigham and Women’s Hospital

    Source link

  • Real-World Data Suggests Stopping Immunotherapy after Two Years is Reasonable in Patients with Advanced Lung Cancer

    Real-World Data Suggests Stopping Immunotherapy after Two Years is Reasonable in Patients with Advanced Lung Cancer

    [ad_1]

    Newswise — CHICAGO – Over the past decade, the approval of immune checkpoint inhibitors has revolutionized treatment for patients with advanced lung cancer, helping many live longer lives and improving overall survival for the disease. However, an important question has remained unanswered: How long should a patient with advanced non-small cell lung cancer (NSCLC), who receives immunotherapy as part of their initial treatment, continue with treatment?

    A new retrospective cohort study, published today in JAMA Oncology and presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9101) by researchers from Penn Medicine’s Abramson Cancer Center, suggests that it’s reasonable to stop immunotherapy treatment at two years as long as their cancer hasn’t progressed. The researchers found no statistically significant difference in overall survival between patients who stopped treatment at two years and those who continued treatment indefinitely.

    “We hope this data provides reassurance that stopping treatment at two years is a valid treatment strategy that does not seem to compromise overall survival,” said lead author Lova Sun, MD, an assistant professor of Hematology-Oncology at the Perelman School of Medicine at University of Pennsylvania. “In the absence of definitive prospective data about the duration of therapy – which will take years to accumulate – our goal was to use real-world observational data to provide guidance on this important clinical question.”

    The appropriate length of treatment remains an open question because pivotal clinical trials have used different treatment durations, and as therapies have been approved and become widely available, many patients have continued therapy beyond the one to two years tested in clinical trials. The longer a patient continues treatment, the higher the health care costs become – both to the patient and to the health care system – and there is ongoing risk of immune-related side effects.

    In this study, the researchers analyzed de-identified data from a national electronic health record that included patients with advanced NSCLC who were treated in both academic and community settings. Of the 1,091 patients who received an immune checkpoint inhibitor as part of their initial therapy (either alone or in combination with chemotherapy) and whose cancer had not continued to grow, only one in five stopped immunotherapy at two years and were considered the “fixed duration” group for this analysis. The vast majority who continued treatment beyond two years were considered the “indefinite duration” group.

    The team analyzed the data and found similar overall survival probabilities between the two groups: 79% for fixed duration and 81% for indefinite duration.

    “Ultimately, the field is still on the leading edge of determining the most appropriate duration for these immunotherapies that have been so effective for patients with advanced lung cancer,” said senior author Charu Aggarwal, MD, MPH, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence in Hematology-Oncology at Penn. “This study provides important data that we hope will help patients feel less worried about potential risks of coming off therapy and more confident if they decide to discontinue treatment after two years.” 

    Sun will share the results in a poster session on Sunday, June 4, at 8 a.m. CT in Hall A.

    ###

    Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $9.9 billion enterprise. 

    The Perelman School of Medicine is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $546 million awarded in the 2021 fiscal year. 

    The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others. 

    Penn Medicine is powered by a talented and dedicated workforce of more than 47,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live. 

    Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2021, Penn Medicine provided more than $619 million to benefit our community.

    [ad_2]

    Perelman School of Medicine at the University of Pennsylvania

    Source link

  • Lung infection may be less transmissible than thought

    Lung infection may be less transmissible than thought

    [ad_1]

    Newswise — A little-known bacterium — a distant cousin of the microbes that cause tuberculosis and leprosy — is emerging as a public health threat capable of causing severe lung infections among vulnerable populations, those with compromised immunity or reduced lung function.

    Recent research found that various strains of the bacterium, Mycobacterium abscessus, were genetically similar, stoking fears that it was spreading from person to person.

    But a new study by Harvard Medical School researchers published May 22 in PNAS, calls those findings into question, offering an alternative explanation behind the genetic similarity of clinical clusters. This suggests that the pathogen may not be that prone to person-to-person transmission after all.

    “Our findings make a strong case for a different explanation behind the observed genetic similarities across strains,” said study senior author Maha Farhat, the Gilbert S. Omenn Associate Professor of Biomedical Informatics at HMS and a pulmonary disease expert at Massachusetts General Hospital. Farhat conducted the work in collaboration with Eric Rubin’s lab at the Harvard T.H. Chan School of Public Health.

    The results, Farhat added, argue against direct person-to-person transmission in clinical settings and instead point to M. abscessus infections being acquired from the home or other environmental exposures.

    In addition to having implications for the precautions that hospitals take to prevent outbreaks, it’s an important new clue into the behavior of a relatively unknown pathogen that poses serious risks for vulnerable populations.

    The research not only contributes to the understanding of M. abscessus transmission, but also suggests scientists should be cautious about assuming human transmission when they see genetic similarities in pathogens more generally, said study first author Nicoletta Commins, who conducted the research as a doctoral candidate at HMS and is now a postdoctoral fellow at the Broad Institute.

    “Our results certainly do not refute the possibility of person-to-person transmission of Mycobacterium abscessus in some cases, and more research is needed to inform best clinical practice for vulnerable patients,” she said. “However, our work supports a model in which person-to-person transmission may not be as common as it is sometimes suggested to be.”

    M. abscessus is a hardy microbe highly resistant to antibiotics and can infect the lungs of immunocompromised people. While it doesn’t pose a threat to most healthy individuals, it can cause severe infection in those with suppressed immunity or people with compromised lung function such as patients with cystic fibrosis, a genetic condition marked by recurrent lung infections and lung scarring. Notably, patients with CF who become infected with this organism become ineligible for lifesaving lung transplants.

    The earlier study that sounded the alarm about person-to-person transmission was based on genetic sequencing of M. abscessus samples obtained from cystic fibrosis patients at clinics in the United States, Australia, and Europe, including the United Kingdom. Researchers found few genetic mutations across the samples — a possible sign that the pathogen was spreading directly between humans.

    For many pathogens such as TB, for example, recent person-to-person transmission leads to only a few or no mutations between any pair of samples simply because the pathogen does not have much time to acquire genetic mutations, Farhat explained.

    “Understandably, observing the genetic similarity between M. abscessus samples caused a great deal of anxiety and fear around how these organisms could be transmitting,” she said.

    Clinicians, especially in clinics that treat cystic fibrosis patients, began taking extra precautions to avert transmission. However, follow-up investigations failed to find supporting evidence that human-to-human transmission was happening, raising questions about other possible explanations for the genetic similarities across samples.

    Farhat’s team set out to investigate a hypothesis that the samples appeared genetically similar because the pathogen was evolving at a very slow rate.

    “We thought, yeah, you observed a small number of mutations, but we don’t know how quickly these mutations are acquired, she explained. “It may be slower than we think, and links between samples that appear recent may not be.’”

    The scientists first used a large dataset of M. abscessus genomes to create a “tree of life,” a kind of genetic family tree for the bacterium.

    They looked at branches of the tree with clusters of genetically similar strains, then tried to calculate their evolutionary rate. They found that these genetically similar clusters were evolving around 10 times more slowly than typical M. abscessus strains.

    Next, they used computer modeling to determine whether the genetic similarities could be explained by the relatively small population size of these bacteria. But even when they simulated extreme population sizes, the result didn’t change. This was an indicator that the high genetic similarity is best explained by a slower evolutionary rate.

    Finally, researchers conducted experiments to see how fast different strains of M. abscessus evolved to develop resistance when exposed to antibiotics in the lab. They found that the genetically similar strains evolved much more slowly than other strains.

    “These are three separate lines of evidence supporting this idea that these clustered isolates of Mycobacterium abscessus are evolving at a slower rate,” Farhat said.

    In addition to reducing concern about person-to-person transmission, the findings provide new insight into a poorly understood pathogen.

    In particular, the results offer clues about how a bug found primarily in the environment adapts and changes after it enters the human body — information that could help scientists eventually understand how to prevent and treat infections.

    Farhat is now planning follow-up studies that would compare bacteria in the environment with samples taken from patients, to better understand why certain patients become infected.

    Authorship, funding, disclosures

    Additional authors included Mark R. Sullivan, Kerry McGowen

    Evan Koch, and Eric Rubin. The work was partly supported by the Damon Runyon Cancer Research Foundation, DRG-2415-20, with additional support from the Orchestra High Performance Compute Cluster at Harvard Medical School, funded by the NIH NCRR 1S10RR028832-01.

    [ad_2]

    Harvard Medical School

    Source link

  • Experts Available on Race-Based Risk for Lung Cancer

    Experts Available on Race-Based Risk for Lung Cancer

    [ad_1]

    Katrina Steiling, MD, MSc
    Assistant Professor of Medicine at Boston University

    Dr. Steiling’s research centers on improving the diagnosis, treatment, and prevention of lung cancer and COPD.

    Kevin C. Wilson, MD
    Professor of Medicine at Boston University

    Dr. Wilson attends in the Outpatient Pulmonary Medicine Clinic, Medical Intensive Care Unit, and Pulmonary Consultation Service at Boston Medical Center. He also serves as the Chief of Documents and Medical Affairs for the American Thoracic Society (ATS), where he oversees the development of clinical practice guidelines and other official documents for the ATS.

    Nirav Bhakta, MD

    Associate Professor at the University of California, San Francisco (UCSF)

    Dr. Bhakta leads human trials to obtain clinical data and tissue samples to understand the molecular basis for variations in the presentation of asthma. His other work advances the application of pulmonary function testing.

    [ad_2]

    Newswise

    Source link

  • One-of-a-kind mobile respiratory system allows researchers to see airborne particle deposits in the lungs in new depths

    One-of-a-kind mobile respiratory system allows researchers to see airborne particle deposits in the lungs in new depths

    [ad_1]

    Newswise — A fully replicated human airway system is a new experimental tool that is overcoming limitations in studying aerosol deposition in lungs at UTHealth Houston School of Public Health.

    The cutting-edge Mobile Aerosol Deposition Apparatus (MALDA), designed and 3D-printed by Wei-Chung Su, PhD, assistant professor of epidemiology, human genetics, and environmental sciences, consists of a head airway, tracheobronchial airways, and a representative section of the alveoli, the tiny air sacs of the lungs that handle gaseous exchange. The system is paired with two particle sizers that measure the particle size distribution of the aerosol of concern in human airways to study lung depositions of the harmful aerosol present in the community or workplace air.

    “By further understanding the chemical composition of the aerosol, we will be able to estimate the inhalation dose of some toxic substances contained in the aerosol, then assess health risks for people who have occupational or environmental exposure,” Su said.

    Aerosol is solid or liquid particles that vary in size ranging from nanometers to micrometers, and can suspend in the air for a long period of time. Those with a diameter of 10 microns or less (PM10), can come from the dust of construction sites, stone cutting, and spray painting, for example; while those with a diameter of 0.1 microns and less (ultrafine particles) can occur in the combustion of gasoline, diesel, or jet fuel. The inhalation and deposition of harmful aerosol in the respiratory tract can lead to various adverse health effects such as chronic obstructive pulmonary disease, pulmonary impairment, cardiovascular disease, and even lung cancer.

    By placing the airway system and particle sizers on a lab trolley with a battery-powered vacuum pump, MALDA is fully mobile and capable of carrying out aerosol respiratory deposition experiments in any real-life environmental and occupational setting. MALDA can be used as a solution for aerosol-related health studies to gather on-site data where it may be impossible to collect human data.

    “MALDA can provide useful experimental data for health research, especially for lung problems caused by aerosol exposure,” Su said.

    The comprehensive replicated human airways allow passage of air into the lung section called tracheobronchial airways which are identified by numerous airway bifurcations (branches). The MALDA airways reach all the way to the 11th airway bifurcation, farther than many previous models that only extended as far as the fourth or fifth airway bifurcation. The extension in airway bifurcations allows Su and his research team to study aerosol respiratory deposition more accurately.

    During his earlier research into occupational aerosol exposure, Su faced many critical limitations and began thinking about ways to improve aerosol respiratory deposition data acquisition. When he began working at the School of Public Health in 2016, he received a pilot research project award from the National Institute for Occupational Safety and Health that gave him the funds to design and 3D-print the MALDA in the UTHealth Houston 3D Printing Service Center. MALDA took nearly two years to build — from designing blueprints, to performance evaluation, to full assembly.

    MALDA has already been applied to several environmental and occupational aerosol exposure studies to estimate aerosol respiratory depositions, including research on welding fumes, e-cigarette aerosol, community ultrafine particles, and aerosol generated from dental cleanings.

    Su and his team are currently working on developing an upgraded MALDA experimental approach to efficiently obtain the deposited mass of aerosol in the human airways to estimate associated health risks.

    “I’m thankful for UTHealth Houston for providing an amazing research environment and resources to allow my dreams to come true,” Su said. “MALDA wasn’t made at a store, but in UTHealth Houston labs with state-of-the-art technology.”

    [ad_2]

    University of Texas Health Science Center at Houston

    Source link

  • Novel Antibiotic Succeeds in Trial Against Hospital-Acquired Pneumonia

    Novel Antibiotic Succeeds in Trial Against Hospital-Acquired Pneumonia

    [ad_1]

    Newswise — A Rutgers researcher leading a trial found that the novel combination antibiotic sulbactam-durlobactam combats dangerous pneumonia at least as well as the best currently approved treatment.

    The findings have led a unanimous expert committee to recommend that the Food and Drug Administration (FDA) approve the new drug, which could be available this summer to combat the often-fatal pneumonia strain known as carbapenem-resistant Acinetobacter baumannii–calcoaceticus complex (ABC), typically acquired in hospitals.

    “Antibiotic-resistant infections are a serious and persistent problem at healthcare facilities, and the [Centers for Disease Control] ranks ABC at the highest level on its threat list,” said Keith Kaye, chief of the Division of Allergy, Immunology and Infectious Disease at Robert Wood Johnson Medical School and first author of the trial report in The Lancet Infectious Diseases. “An estimated 8,500 hospital-acquired cases killed 700 patients and cost $280 million in 2019, so we greatly needed a breakthrough treatment like sulbactam-durlobactam.”

    The trial gave imipenem–cilastatin to 181 patients with laboratory-confirmed ABC and then randomized them to additional treatment with either sulbactam–durlobactam or the best existing treatment, an antibiotic called colistin. Mortality due to multiple causes after 28 days was 12 of 63 (19 percent) in the sulbactam–durlobactam group and 20 of 62 (32 percent) in the colistin group.

    The trial was large enough to prove that sulbactam-durlobactam prevents at least as many fatalities as colistin but not large enough to prove its superiority in this trial will persist in real-world use, though it may.

    The trial results did prove that sulbactam-durlobactam beats colistin in one crucial respect: tolerability. Kidney injury, serious adverse events and all treatment-related adverse events were significantly lower for patients who received sulbactam-durlobactam than for patients who received colistin.

    Another advantage of the novel antibiotic is dosing. All patients receive the same injectable dose of sulbactam–durlobactam. Doses of colistin in the study, on the other hand, varied with patient weight, so it’s considerably easier for providers to prescribe or administer the wrong amount.

    As its name implies, sulbactam-durlobactam combines two drugs. Sulbactam has been approved for use since 1986, but durlobactam is new and has yet to win approval. That could change soon, however. The FDA’s Antimicrobial Drugs Advisory Committee reviewed advance results of the new trial, along with earlier studies, and recommended on April 17 that the FDA approve the new combination for ABC treatment.

    FDA officials are free to reject such recommendations but almost always follow recommendations from advisory committees, which comprise independent experts on particular classes of disease and medication.

    “If all moves quickly, infected patients could begin receiving sulbactam-durlobactam as part of normal clinical care the second half of this year,” Kaye said. “Unfortunately, sulbactam-durlobactam isn’t the sort of wide-spectrum antibiotic that could prove effective in treating a wide variety of antibiotic-resistant infections, but it’s very good at treating this particularly dangerous one, and that’s a significant win.”

    [ad_2]

    Rutgers University-New Brunswick

    Source link

  • Surgical resection is associated with superior 5-year survival compared to stereotactic body radiotherapy for early-stage lung cancer in healthy patients

    Surgical resection is associated with superior 5-year survival compared to stereotactic body radiotherapy for early-stage lung cancer in healthy patients

    [ad_1]

    Newswise — Stereotactic body radiotherapy (SBRT) is being used increasingly in early-stage lung cancer.  Between 2012 and 2018, the proportion of otherwise healthy patients treated with SBRT increased from 15 to 26%.  

    A study at the Yale University School of Medicine looked at data from the National Cancer Database for this six-year period and compared the 5-year survival rates for patients who had surgical resection and patients who elected to have SBRT. Overall, 30,658 patients were identified, including 24,729 (80.7%) who underwent surgery and 5,929 (19.3%) treated with SBRT.

    In propensity-matched patients, survival favored SBRT for the first several months, but reversed after one year and long-term significantly favored surgical management (5-year survival 71.0% for surgery vs. 41.8% for SBRT). When the propensity-matched analysis was repeated to only include SBRT patients who had documented refusal of a recommended surgery, surgical management again had a superior 5-year survival with (71.4% vs. 55.9%).

    The increasing usage of SBRT in otherwise healthy individuals represents a potential loss in life years for patients with early-stage NSCLC. Among patients that are eligible for either treatment, long-term survival favors surgical management, particularly for patients with a health-related life expectancy exceeding two years.

    Brooks Udelsman, MD, will present this study looking at some of the reasons patients opt for SBRT, Monday, May 8, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    [ad_2]

    American Association for Thoracic Surgery (AATS)

    Source link

  • Clinical Outcomes of more than 500 Lung Transplants using Ex vivo Lung Perfusion: A Large-Volume, Single-Center Retrospective Analysis

    Clinical Outcomes of more than 500 Lung Transplants using Ex vivo Lung Perfusion: A Large-Volume, Single-Center Retrospective Analysis

    [ad_1]

    Newswise — To compare the outcomes of patients receiving lungs transplanted after undergoing ex vivo lung perfusion (EVLP) versus those transplanted conventionally at the Toronto General Hospital, Aadil Ali, PhD, and coauthors looked at 14 years of data from the Toronto Lung Transplant Database. 

    Patients were separated based on whether they received lungs that underwent EVLP or whether they were transplanted conventionally (controls). They were matched 1:1 based on medical diagnosis, recipient status, recipient sex, recipient age, BMI, donor age, and calendar year. The group found no differences in the incidence of Primary Graft Dysfunction (PGD) Grade 3 at 72h, post-transplant mechanical ventilation, post-transplant hospital length of stay, intensive care unit (ICU) length of stay, allograft survival analysis, and CLAD-Free survival analysis.

    Dr. Ali and his associates report that “EVLP has been successfully incorporated in our program for more than a decade and is an effective method to expand the organ donor pool without compromising post-transplant outcomes.”

    Dr. Ali will present the results of this study Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    [ad_2]

    American Association for Thoracic Surgery (AATS)

    Source link

  • Long-term Outcome of Patients with Peripheral Ground Glass Opacity Dominant Lung Cancer After Sublobar Resections

    Long-term Outcome of Patients with Peripheral Ground Glass Opacity Dominant Lung Cancer After Sublobar Resections

    [ad_1]

    Newswise — In 2011, Makoto Suzuki, MD, and a team of associates from across Japan embarked on a long-term study of the safety and efficacy of sublobar resections for ground-glass opacity–dominant (GGO) peripheral lung cancer. When the group began the study, the optimal mode of surgery for GGO–dominant peripheral lung cancer defined with thoracic thin-section computed tomography was speculated as sublobar resection but not proven. At that time, the planned sample size was 330 with the expected 5-year relapse-free survival of 98% and a threshold of 95%.

    Between May 2009 and April 2011, 333 patients were enrolled from 51 institutions in Japan (median age was 62 at registration) and followed until May 6, 2021. Among that group, sublobar resections were performed in 314 patients (258 wedge resections and 56 segmentectomies), conversion lobectomies were performed in 11 patients, and eight were ineligible.  

    At five years, the group concluded that sublobar resection with enough surgical margin offered sufficient local control and relapse-free survival for lung cancer clinically resectable N0 staged by thin-section computed tomography with 3 or fewer peripheral lesions 2.0 cm or less amenable to sublobar resection and with a consolidation tumor ratio of 0.25 or less.

    At 10 years, the group can now report the reintervention-free survival of 98.6% and the overall survival of 98.5% for the 314 patients with sublobar resections. It concludes that the long-term results from their study suggest that sublobar resection for peripheral GGO-dominant lung cancer patients is a surgical procedure that can fully cure them of the disease. The indication of other treatment options should be further investigated.

    Dr. Suzuki will present this study Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    [ad_2]

    American Association for Thoracic Surgery (AATS)

    Source link

  • Results of Early Monitoring of Circulating Tumor DNA in Resected Early-Stage Non-Small Cell Lung Cancer

    Results of Early Monitoring of Circulating Tumor DNA in Resected Early-Stage Non-Small Cell Lung Cancer

    [ad_1]

    Newswise — Among the questions that cancer patients ask following their surgeries are, “Will it come back? Do I need additional treatment?”

    Circulating tumor DNA (ctDNA) offers a possible tool for answering those questions. ctDNA found in the bloodstream comes from cancerous cells and tumors; and monitoring ctDNA in patients with resected early-stage non-small cell lung cancer (NSCLC) could aid in detecting and managing recurrence. 

    Aaron Dinerman, MD, Baylor University Medical Center, Baylor Scott & White System, and coauthors evaluated the impact of early real-world experience of monitoring ctDNA among these patients.

    Beginning in October 2021, post-operative ctDNA was monitored for all surgically resected NSCLC patients (76) at the Baylor Medical Center. Peripheral blood samples were collected for ctDNA at 3-month intervals. Of those 76 patients, eight were positive for ctDNA. Post-operative clinical care was altered for seven of the eight; five received an earlier surveillance CT scan, and six received early PET-CT scan. Six of the ctDNA-positive patients had a biopsy-proven recurrence and were directed into therapy; two have not demonstrated radiographic evidence of recurrence but were directed into earlier interval surveillance.

    The serial monitoring of ctDNA following resection of early-stage NSCLC resulted in early detection of recurrent cancer and led to early surveillance and/or unexpected medical oncology referral in seven of the eight patients with positive ctDNA. (One patient demonstrated recurrence [brain metastases] with a negative ctDNA level.) This study exemplifies the impact of ctDNA on surveillance and management in early stage resected NSCLC. Further multicenter studies are required to determine protocol-specific best practices. 

     

    Travis Martin, DO, of the University of North Texas Health Science Center, will present the results of this study and its implications Sunday, May 7, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    [ad_2]

    American Association for Thoracic Surgery (AATS)

    Source link

  • Safety and Efficacy of Delaying Nighttime Lung Transplantation

    Safety and Efficacy of Delaying Nighttime Lung Transplantation

    [ad_1]

    Newswise — Lung transplantation is routinely performed at night because of the unpredictability of donor organ procurement. Late start-times for complex operations such as lung transplantation have been associated with adverse outcomes. There are numerous reasons that delaying transplantation to the morning is preferable: Rested teams perform better; the well-being of the entire team is affected by long after-hours work; and during the day, more help is available for any intraoperative complications. 

    But is it safe to wait? Can cross clamp and cold ischemia times be extended? How does delaying the surgery impact the outcomes?

    Samuel T. Kim and colleagues at the University of California Los Angeles hypothesized that for donors with cross clamp times occurring after 1:30 a.m., the recipient operation could be delayed until morning with acceptable outcomes. Consented adult lung transplant recipients from March 2018 to May 2022 with donor cross-clamp times between 1:30 a.m. and 5:00 a.m. were prospectively enrolled in this study (34 patients; Night cohort); and their skin incision times were set at 6:30 a.m. A control group was identified and included recipients of donors with cross clamp times occurring at any other time of day (68 patients; Day cohort).

    Dr. Kim and his team examined short- and medium-term outcomes, including early mortality, a composite of post-operative complications, lengths of stay (ICU and total), 1- and 3-yr survival,) and chronic lung allograft dysfunction at 3-years between the two groups. The results for each of these comparisons were statistically similar.

    The group concluded that lung transplant recipients with donor cross clamp times scheduled after 1:30 a.m. can have their operations delayed safely until 6:30 a.m. with acceptable outcomes. And in experienced lung transplant centers, adoption of such a policy may lead to alternative workflow and improved team well-being.

    Dr. Kim will present this study Saturday, May, 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    [ad_2]

    American Association for Thoracic Surgery (AATS)

    Source link

  • Disparities in Racial/Ethnic Representation and Salary among Academic Cardiothoracic Surgeons

    Disparities in Racial/Ethnic Representation and Salary among Academic Cardiothoracic Surgeons

    [ad_1]

    Newswise — The American Association for Thoracic Surgery (AATS) is committed to diversity, equity, and inclusion. A wealth of data has shown that diversity in the physician workforce improves patient care, safety, physician well-being, and innovation; and fair compensation is essential to culturing a diverse workforce.

    To learn more about how race and ethnicity are related to compensation, diverse group of academic cardiothoracic surgeons led by Cherie P. Erkmen, MD, of Temple University, looked at the racial and ethnic representation among academic cardiothoracic surgeons. The group also analyzed salaries of cardiothoracic surgeons based on race/ethnicity. 

    Dr. Erkmen and her team looked at cross-sectional data collected by Association of American Medical Colleges Faculty Data for U.S. Medical Schools, which reported academic rank, race/ethnicity, and mean and median compensation. Their analysis reveals low diversity in the cardiothoracic workforce, especially at the advanced academic rank of professor. Black/African American cardiothoracic surgeons had lower salary than their colleagues, a difference that persisted at all academic ranks. Hispanic/LatinX and Asian cardiothoracic surgeons at lower academic ranks also experienced salary disparity, but equal or greater salaries compared with their colleagues when achieving the academic ranks of associate professor or professor. According to Dr. Erkmen, “These data demonstrate that the relationship between race/ethnicity and compensation is complex. Future studies are needed to understand mechanisms of salary disparity.” Dr. Erkmen concluded, “Our profession and our patients will benefit from a diverse workforce. Hopefully our work will someday lead to the development of best practices for equitable compensation that will support all cardiothoracic surgeons.”

    Dr. Erkmen will present this study on Saturday, May 6, at the AATS 103rd Annual Meeting in Los Angeles.

     

    Ethnicitya                          Overall             Professors               Salary comparison b

    White                                  65%                  78%

    Asian                                  25.2%                15%                        71-102%

    Hispanic/Latino                    4.0%                  3%                         86-130%

    Black/African American        3.3%                  2%                         76-85%

    a1.5% were multiple/other race and 0.4% were American Indian/Alaskan Indian.

    bPercentage of the mean and median salary earned by White cardiothoracic surgeons.

     

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

    [ad_2]

    American Association for Thoracic Surgery (AATS)

    Source link

  • The Early Outcome of Lung Transplantation from Donors who Tested Positive for COVID-19

    The Early Outcome of Lung Transplantation from Donors who Tested Positive for COVID-19

    [ad_1]

    Newswise — The effects of the COVID-19 pandemic have rumbled through every piece of society, and nowhere more dramatically than in the medical communities.

    Takashi Harano, MD, and colleagues at Keck Medicine, University of Southern California, analyzed lung transplantation data from April 2020 to June 2022, to identify the early outcomes for patients who received lungs from COVID-19–positive donors. 

    Of the 29,944 donors identified by the Organ Procurement and Transplantation Network/United Network for Organ Sharing during that time, 1,297 were COVID-19 positive (4.3%). Lungs were transplanted from 47 donors.

    The recipients of allografts from those 47 donors had higher Lung Allocation Scores and more frequently underwent double lung transplantation (43/47). The post-transplant length of hospital stay, needs of Extracorporeal membrane oxygenation at 72 hours after transplantation, and survival outcomes were comparable between the two groups.

    This study reports that carefully selected lung allografts from COVID-19–positive donors had comparable early post-transplant outcomes to the lung allografts from COVID-19-negative donors. 

    Dr. Harano will present the results of this study Saturday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    [ad_2]

    American Association for Thoracic Surgery (AATS)

    Source link

  • Air Quality and Lung Cancer in Wayne County, Mich.—a Large Urban/Suburban Study

    Air Quality and Lung Cancer in Wayne County, Mich.—a Large Urban/Suburban Study

    [ad_1]

    Newswise — Lung cancer is the most common cause of cancer-related deaths in North America. Although cigarette smoking remains the main risk factor for lung cancer development, the importance of environmental factors such as pollution and poor air quality is becoming increasingly recognized. Excessive exposure to air pollutants, frequently found in larger urban areas, can lead to negative health outcomes including lung cancer.

    To understand the relationship between specific environmental pollutants and lung cancer in a large urban county in Michigan, Hollis E. Hutchings, MD, and a research group out of the Henry Ford Health System in Detroit analyzed comprehensive lung cancer information and air pollution data encompassing more than three decades. The group investigated the spatial relationship of lung cancer incidence within Wayne County over time and used air pollutant data from the U.S. Environmental Protection Agency to analyze the relationship between pollutant levels and the incidence of lung cancer.

    The group identified 58,866 cases of lung cancer. There were three major clusters of lung cancer incidence in the county. The most intense clusters were in downtown Detroit and the heavily industrialized downriver area. Sulfur dioxide (SO2) had the strongest statistical correlation with lung cancer. Particulate matter 10 (PM10), nitric oxide (NO2), volatile organic compounds (VOCs) and ozone levels also had statistically significant correlations with incidence.

    Based on these data, the group suggests that resident health in areas with poor air quality may benefit from targeted interventions such as campaigns for lung cancer screening and reduction of pollutants. Residential history may also be important when counseling individual patients with lung disease.

    Dr. Hutchings will present the results of this study Sunday, May 6, at the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting in Los Angeles.

    ###

    Attribution to the American Association for Thoracic Surgery (AATS) 103rd Annual Meeting is requested in all coverage.

     

    ABOUT AATS

    The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premier association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit aats.org to learn more.

     

    [ad_2]

    American Association for Thoracic Surgery (AATS)

    Source link

  • Coal Trains Polluting San Francisco Bay Air

    Coal Trains Polluting San Francisco Bay Air

    [ad_1]

    Newswise — As per a study conducted by the University of California, Davis in Richmond, California, coal trains and terminal operations are found to be major contributors of fine particulate matter (PM2.5) pollution to urban areas. It has been observed that they contribute more significantly to this pollution as compared to other freight or passenger trains.

    According to a study published in the journal Air Quality, Atmosphere & Health, it is the first research conducted in a U.S. urban area that examined particulate pollution caused by coal trains. The study is also the first of its kind to utilize artificial intelligence technologies to verify that the air pollution detected has originated from coal.

    The study revealed that coal-carrying trains passing through an area contribute an average of 8 micrograms per cubic meter of air (ug/m3) to the existing ambient PM2.5 pollution. This amount is 2 to 3 ug/m3 more than the pollution contributed by freight trains. Furthermore, even empty coal cars were found to add about 2 ug/m3 of coal dust traces to the air. In certain wind conditions, the concentrations of PM2.5 reached up to 25 ug/m3.

    Environmental justice concerns

    The authors of the study recently released a comprehensive report to the California Air Resources Board. The report includes additional measurements of coal and petroleum coke emissions (a byproduct of oil refining), which show that the storage and handling of these materials at shipping terminals and train holding yards also contribute to the emission of PM2.5. Furthermore, the report demonstrated that this particulate matter pollution from coal and petroleum coke reaches residential communities, thereby impacting public health.

    As per the study conducted by the University of California, Davis in Richmond, California, coal trains and terminal operations contribute a substantial quantity of fine particulate matter (PM2.5) pollution to urban areas. The study suggests that their contribution to this pollution is more significant than other types of freight or passenger trains.

    According to a research paper published in the journal Air Quality, Atmosphere & Health, it is the first-ever study of coal train particulate pollution conducted in a U.S. urban area. The study is also the first to leverage artificial intelligence technologies to verify that the detected source of air pollution is from coal.

    The study revealed that passing trains carrying coal contribute an average of 8 micrograms per cubic meter of air (ug/m3) to ambient PM2.5 pollution. This amount is 2 to 3 ug/m3 more than the pollution caused by freight trains. Interestingly, even empty coal cars were found to add around 2 ug/m3 of coal dust traces to the air. Under certain wind conditions, these concentrations of PM2.5 reached up to 25 ug/m3.

    Environmental justice concerns

    The authors of the study have recently submitted a complete report to the California Air Resources Board. The report includes additional measurements of coal and petroleum coke emissions (a byproduct of oil refining). It clearly shows that the storage and handling of these materials at shipping terminals and train holding yards also release PM2.5 emissions, and that this pollution travels to residential communities. This suggests that the adverse effects of coal-related pollution are not just limited to the areas near coal mines or power plants but also extend to urban areas where coal transport and storage occur.

    In addition to providing more measurements of coal and petroleum coke emissions, the report also discusses the health and environmental justice implications of coal-related pollution for residents living in Richmond and nearby Oakland. This is particularly relevant as a proposal for a coal terminal is currently under discussion in Oakland. The report suggests that such a proposal would have significant negative impacts on the air quality and health of the surrounding communities.

    The study involved placing a monitor along train tracks in Richmond, a city located in the San Francisco Bay Area, between May 2022 and October 2022. Richmond is home to a racially diverse population of approximately 115,000 people, with high rates of asthma and heart disease. The study also involved monitoring in other locations over the past two years.

    The authors found that coal transport, storage and handling significantly increase community exposure to ambient PM2.5.

    According to Spada, the lead author of the study, the scale of the project motivated the team to experiment with computer-learning techniques. As a result, they developed a state-of-the-art system that allowed for the classification of several thousand trains observed during the study with a high degree of confidence. This included various types of trains, such as passenger, freight, and both unloaded and full coal cars. The success of this approach highlights the potential of artificial intelligence in environmental research.

    The researchers noted that an unforeseen benefit of using computer-learning techniques to classify train types based on their pollution emissions was that this technology can also be applied to help identify the sources and levels of pollution in other air pollution concerns. For instance, the same approach could be used to analyze emissions from refinery flaring, construction dust, and activities such as unloading and loading at shipyards. This demonstrates the potential for this technology to be used in a broader range of environmental research and monitoring efforts.

    No safe level

    The World Health Organization and the U.S. Environmental Protection Agency have stated that there is no known safe level of PM2.5 pollution. A recent study on the global burden of disease estimates that fine particulate matter pollution is a contributing factor in 6.7 million deaths worldwide each year.

    The authors noted that the negative effects of air pollution are disproportionately experienced by vulnerable populations, such as infants, children, the elderly, people of color, those with low incomes, and those with underlying health conditions.

    According to the scientists, the study did not measure ultrafine or coarse particles (PM10), which are also produced along with PM2.5. This suggests that the study probably underestimates the true health risks posed by passing coal trains.

    The study was funded by the California Air Resources Board Community Air Monitoring Grant Program.

    [ad_2]

    University of California, Davis

    Source link

  • Suffering from allergies already? Blame climate change.

    Suffering from allergies already? Blame climate change.

    [ad_1]

    Reports indicate that pollen patterns, magnitude and flowering timing are changing with the earth’s temperature rise

    Human-caused climate change is exacerbating pollen seasons, asthma and even wildfires in certain areas around the nation. In the past three decades across the U.S., pollen seasons have not only started sooner and lasted longer but also increased in pollen concentrations. This trajectory showcases that its more than just a seasonal nuisance now. Allergies to airborne pollen are tied to respiratory health and will impact a very similar vulnerable population that suffered during the COVID-19 pandemic.

    For expert commentary on allergies and asthma that have been categorized as a health outcome linked to climate change, Andrea De Vizcaya Ruiz, PhD, associate professor and Shahir Masri, ScD, associate specialist, both with the environmental and occupational health department at UC Irvine Program in Public Health, are available for interviews.

    More pollen circulating in our air longer is contributing to the onset and aggravation of allergies (rhinitis, eye irritation, headaches, cough, post-nasal drip). Coupled with indoor air pollution and climate change, our communities are experiencing unprecedented exposure to harmful air pollutants. The evidence is alarming and is imperative we take action to adopt effective and evidence-based regulations, spread awareness on lifestyle changes, and work together to clean our air.

    [ad_2]

    University of California, Irvine

    Source link

  • 240 Mammal Genomes Reveal Human Disease Risks

    240 Mammal Genomes Reveal Human Disease Risks

    [ad_1]

    Newswise — Why is it that certain mammals have an exceptional sense of smell, some hibernate, and yet others, including humans, are predisposed to disease? A major international research project, jointly led by Uppsala University, Sweden and the Broad Institute, USA, has surveyed and analysed the genomes of 240 different mammals. The results, now published in 11 articles in the journal Science, show how the genomes of humans and other mammals have developed over the course of evolution. The research shows which regions have important functions in mammals, which genetic changes have led to specific characteristics in different species and which mutations can cause disease.

    “In combination, the 11 articles we are now publishing in Science provide an enormous amount of information about the function and development of mammalian genomes,” says Kerstin Lindblad-Toh, Professor of Comparative Genomics at Uppsala University and one of two leaders of the international consortium of researchers. “Moreover, we have produced data that can be used for studies of evolution and medical research for many years to come.”

    In a large international project jointly led by Uppsala University and the Broad Institute, more than 30 research teams have together surveyed and analysed the genomes of 240 mammal species. The results, now published in 11 articles in the journal Science, show how the genomes of humans and other mammals have developed in the course of evolution.

    The human genome contains approximately 20,000 genes that constitute the code for manufacturing all the proteins in the body. The genome also contains instructions that direct where, when and how much of the proteins are produced. These parts of the genome, which are called regulatory elements, are much more difficult to identify than the parts that give rise to proteins. However, studying a great many mammals’ genomes makes it possible to figure out which parts of the genome are functionally important.

    The hypothesis shared by the researchers behind the publications in Science has been that if a position in the genome has been preserved throughout 100 million years of evolution, it likely serves a function in all mammals. For the first time, they have been able to test this hypothesis on a large scale. By making a detailed survey and systematic comparison of the genomes of 240 mammals, the researchers have identified regions of the human genome with previously uncharacterised function. These regions are likely regulatory elements and are significant for the correct functioning of the genome. Mutations in these can play an important role in the origin of diseases or in the distinctive features of mammal species.

    The researchers identified more than three million important regulatory elements in the human genome, about half of which were previously unknown. They were also able to ascertain that at least 10 per cent of the genome is functional, ten times as much as the approximately one per cent that codes for proteins.

    The 240 different mammals in the study vary widely in their characteristics, such as the acuteness of their sense of smell or the size of their brain. The researchers were able to find regions in the genomes that lead to some species having a superior sense of smell or to certain species hibernating.

    “It’s exciting to now have a picture of which mutations have steered the development of specific traits in these widely divergent mammals,” says Matthew Christmas, researcher and co-first author of one of the articles focusing on the function of the genome and how it affects distinctive features in different species.

    One of the studies shows that mammals had begun to change and diverge ven before the Earth was hit by the asteroid that killed the dinosaurs, approximately 65 million years ago.

    “Our results can also provide important information about whether mammals are at risk of extinction, depending on how much variation they have in their genome. This is information that can lay the foundation for understanding how to manage a species to help it survive,” says Professor Lindblad-Toh.

    The new knowledge also helps researchers understand how diseases arise, by linking the positions in the genome conserved by evolution to known conditions. This can be done for all species and will also be usable with reference to human diseases.

    “Our analyses of 240 mammals give us a better insight into the regulatory signals in the genome. We calibrated our results on positions that are known to contribute to disease, and then could use these to suggest additional positions which could be prioritised for neurological traits, such as schizophrenia or immune conditions including asthma or eczema,” says Jennifer Meadows, researcher and co-first author of the second article, which focuses on how the project’s data can contribute to knowledge about diseases.

    The genome of healthy and sick people is compared to understand which mutations lead to disease. This produces a picture of the region in the genome that may be important, but does not yield an exact knowledge of which mutation causes the disease.

    “A large proportion of the mutations that lead to common diseases, like diabetes or obsessive-compulsive disorder, lie outside the genes and have to do with gene regulation. Our studies make it easier to identify the mutations that lead to disease and to understand what goes wrong,” says Lindblad-Toh.

    The researchers also studied the cancer medulloblastoma, which is the most common type of malignant brain tumour in children. Although modern treatments have improved the prognosis, not all children can be cured. Moreover, those that survive often experience lifelong side-effects from the aggressive treatment.

    “In patients with medulloblastoma, we found many new mutations in evolutionarily conserved positions. We hope that analysis of these mutations will lay the ground for new diagnostics and therapies,” says Karin Forsberg-Nilsson, Professor of Stem Cell Research at Uppsala University, who led the cancer part of the study.

    This work was supported in part by the National Institutes of Health (US), the Swedish Research Council (SWE), the Knut and Alice Wallenberg Foundation (SWE), and the National Science Foundation (US).

    [ad_2]

    Uppsala University

    Source link

  • Peripheral Nerve Blocks in Total Joint Arthroplasty May Provide the Best Reduction in Complications in Older Patients With Fewer Comorbidities

    Peripheral Nerve Blocks in Total Joint Arthroplasty May Provide the Best Reduction in Complications in Older Patients With Fewer Comorbidities

    [ad_1]

    Newswise — Hollywood, Florida, April 22, 2023 — In a study conducted at Hospital for Special Surgery (HSS), researchers found that the use of peripheral nerve blocks in total knee and total hip arthroplasty were associated with a consistent reduction in risk for postoperative complications in patients with a lower comorbidity burden. In particular, the most consistent reduction in risk of complications and use of hospital resources was in older patients with no comorbidity burden. These findings were presented at the 2023 Spring American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Meeting and were acknowledged as one of the President’s Choice Abstracts.1

    “The utility of interventions in a general population of patients might be difficult to show, but might differ by subgroups, with certain patients deriving benefit when others do not,” said Stavros G. Memtsoudis, MD, PhD MBA FCCP, an anesthesiologist at HSS and lead author of the study. “In this study, we tried to identify which subgroups might benefit most from peripheral nerve blocks in terms of a reduction in complications after joint arthroplasty.”

    These findings demonstrate that comorbidities may be a factor with a greater effect on complication risk than other factors, such as age, and that peripheral nerve blocks alone may not be sufficient to consistently influence outcomes in patients with comorbidities.

    These findings may also demonstrate that there may be a specific optimal baseline patient population for whom peripheral nerve blocks have the greatest impact on improving surgical outcomes: patients who are older but do not have many comorbidities. This study could help clinicians determine which surgical patients may benefit most from peripheral nerve blocks and which candidates may need additional measures to improve their outcomes.

    Many total joint arthroplasty (TJA) patients are at risk for poorly controlled pain and complications. The number of these surgeries performed increases each year, underscoring the importance of finding solutions. To find out how uniformly peripheral nerve blocks can improve perioperative outcomes and pain relief in TJA patients, the researchers conducted a population-based analysis using data from TJA surgeries in the United States from January 2006 to December 2019.

    Patients were divided into nine groups based on age and number of comorbidities. Age was broken down as follows: Young (Y) = younger than 65 years; Middle (M) = 65 to 75 years; and Old (O) = older than 75 years. Comorbidities were categorized as: no pre-existing comorbidity (Group 1); 1 or 2 comorbidities (Group 2); and 3 or more comorbidities (Group 3). This led to a breakdown of nine groups total: Y1, Y2, Y3, M1, M2, M3, O1, O2, and O3.

    The sample included more than 2.8 million TJA cases performed in 887 hospitals. Of those, 15.5% received a peripheral nerve block. The overall rate of peripheral nerve blocks increased from 9.5% in 2006 to 18.9% in 2019. Peripheral nerve blocks were used least often in young patients with more than 3 comorbidities (13.9%) and used most often in middle-aged patients with no comorbidities (16.3%). Peripheral nerve blocks were associated with a significant reduction in the odds of respiratory complication, acute renal failure, delirium, ICU admission, high opioid consumption during hospitalization, and prolonged length of stay.

    The results showed reduced odds of respiratory complications for the O1 and Y2 groups, reduced odds of acute renal failure in the Y1, O1, and M2 groups, and reduced odds of delirium in O1. The risk for ICU admission was reduced in those who received peripheral nerve blocks in all ages with no comorbidities, as well as in the Y2 and O2 groups, compared with those who did not receive a peripheral nerve block. Peripheral nerve blocks also reduced the odds of a prolonged length of stay in the Y1, M1, Y2, M2, and Y3 groups. Odds of high opioid use in patients who received a peripheral nerve block versus no peripheral nerve block were significantly reduced in all groups except for Y3 and O3.

    “While peripheral nerve blocks might have the advantage of providing superior pain control versus systemic modalities as well as reducing opioid consumption, a reduction in complications might be expected in those without comorbidities,” Dr. Memtsoudis said. “However, given that peripheral nerve blocks still provide better pain control and reduce opioid use, all patients should be considered for peripheral nerve blocks.”

    “Older patients without major comorbidities might represent a subgroup in which the beneficial effects of peripheral nerve blocks are most likely to be expected,” he noted. “This might be the case because major comorbidities are a bigger determinant of complications, with peripheral nerve blocks being less likely to be able to exert a substantial effect.”

    Future research should include further examination of the benefits of peripheral nerve blocks. “Many questions remain unanswered, including quantification of attributable risk reduction of peripheral nerve blocks and which peripheral nerve blocks provide the biggest effect,” Dr. Memtsoudis concluded.

     

    References

    1. Haoyan Zhong MPA, Marko Popovic BS, Jashvant Poeran MD PhD, Crispiana Cozowicz MD, Alex Illescas MPH, Jiabin Liu MD PhD, Stavros G Memtsoudis MD PhD MBA FCCP. “Does the impact of peripheral nerve blocks vary by age and comorbidity subgroups? A nationwide population based study.” Presented at: 48th Annual Regional Anesthesiology and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA), April 20-22, 2023; Hollywood, FL.

     

    About HSS

    HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the 13th consecutive year), No. 3 in rheumatology by U.S. News & World Report (2022-2023), and the best pediatric orthopedic hospital in NY, NJ and CT by U.S. News & World Report “Best Children’s Hospitals” list (2022-2023). In a survey of medical professionals in more than 20 countries by Newsweek, HSS is ranked world #1 in orthopedics for a third consecutive year (2023). Founded in 1863, the Hospital has the lowest complication and readmission rates in the nation for orthopedics, and among the lowest infection rates. HSS was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center five consecutive times. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State, as well as in Florida. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Innovation Institute works to realize the potential of new drugs, therapeutics and devices. The HSS Education Institute is a trusted leader in advancing musculoskeletal knowledge and research for physicians, nurses, allied health professionals, academic trainees, and consumers in more than 145 countries. The institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally. www.hss.edu.

    [ad_2]

    Hospital for Special Surgery

    Source link

  • Cleveland Clinic-Led Study Suggests More Patients with Community-Acquired Pneumonia Could Be Switched from IV to Oral Antibiotics Earlier

    Cleveland Clinic-Led Study Suggests More Patients with Community-Acquired Pneumonia Could Be Switched from IV to Oral Antibiotics Earlier

    [ad_1]

    Newswise — Friday, April 21, 2023, CLEVELAND: Findings from a Cleveland Clinic-led study showed for patients with community-acquired pneumonia treated with intravenous (IV) antibiotics, earlier switching to oral antibiotics in clinically stable patients was associated with shorter duration of antibiotics and hospital stay. 

    The results from this retrospective study, led by Abhishek Deshpande, M.D., Ph.D., a staff physician investigator in the Center for Value-Based Care Research and Michael B. Rothberg, M.D., vice chair of research, Cleveland Clinic Community Care, were recently published in Clinical Infectious Diseases

    Current clinical practice guidelines from the American Thoracic Society/Infectious Diseases Society of America recommend switching from IV to oral antibiotics once patients are clinically stable, which is typically after three days of IV therapy. Early switching in stable patients appears safe but data showed it occurred infrequently in patients with community-acquired pneumonia.

    For the study, researchers analyzed data from a national cohort of 378,041 adult patients from 642 hospitals in the U.S. from 2010 to 2015 who were admitted to the hospital with community-acquired pneumonia and initially treated with IV antibiotics. 

    Of this patient group, approximately six percent were switched early from IV antibiotics to oral antibiotics on or before hospital day three, and 30% were switched before discharge. Early switching to oral antibiotics was associated with shorter length of stay and shorter duration of antibiotic treatment and was not associated with worse outcomes. 

    Despite the evidence for safety of early switching in stable patients, the study found most patients received IV therapy throughout their hospital stay. The data highlights the opportunity for hospitals to reduce the burden of antibiotics by encouraging clinicians to follow evidence-based recommendations to switch therapy in clinically stable patients with community-acquired pneumonia.

    “Community-acquired pneumonia is a leading cause of hospitalizations and antibiotic use,” said Dr. Deshpande. “Optimizing the delivery of antibiotics is crucial, as prolonged exposure can lead to increased antibiotic resistance and healthcare-associated infections. Our research suggests many more patients could be switched earlier without compromising outcomes.”

    Over 1 million adults in the United States are hospitalized each year for pneumonia and 50,000 of those die from the disease. The best way to prevent pneumonia is to get vaccinated against bacteria and viruses that commonly cause it.

     

    About Cleveland Clinic

    Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Among Cleveland Clinic’s 77,000 employees worldwide are more than 5,658 salaried physicians and researchers, and 19,000 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,665-bed health system that includes a 173-acre main campus near downtown Cleveland, 22 hospitals, more than 275 outpatient facilities, including locations in northeast Ohio; southeast Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2022, there were 12.8 million outpatient encounters, 303,000 hospital admissions and observations, and 270,000 surgeries and procedures throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 185 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/ClevelandClinic. News and resources available at newsroom.clevelandclinic.org.

     

    Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request. 

     

    ###

    [ad_2]

    Cleveland Clinic

    Source link